Log in with your email address username.

×

[Department of Error] Department of Error

Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390: 276–88– In the findings section in the summary of this Article, the sentence “186 patients (59%) in the 200 mg group, and 168 patients (55%) in the 100 mg group achieved PASI 75, compared with …”, should have read “186 patients (59%) in the 200 mg group, and 168 patients (55%) in the 100 mg group achieved a PGA response, compared with …”.

email